Related Experiment Video
Updated: May 4, 2026

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity
Published on: November 16, 2016
A case-based approach to evaluating azithromycin use and cardiovascular risks
Elaine Wong1, Timothy V Nguyen1
1Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York.
Abstract:
Azithromycin is a commonly prescribed macrolide antibiotic for the management of community-acquired pneumonia in the outpatient setting. Recent data have led to a growing concern of abnormal changes in cardiac electrophysiology and arrhythmias associated with its use. As azithromycin continues to be prescribed, clinicians should be aware of the new safety data and how it may affect concomitant medications or comorbid conditions in a patient. This article utilizes a case-based approach to assess azithromycin use and the risk of QT-prolongation and cardiac arrhythmias.
Insights
Azithromycin, an antibiotic for pneumonia, may increase the risk of heart rhythm problems like QT prolongation. Clinicians should review updated safety data for patient care.
Area of Science:
- Pharmacology
- Cardiology
- Infectious Diseases
Background:
- Azithromycin is a widely used macrolide antibiotic for community-acquired pneumonia.
- Concerns are rising regarding azithromycin's potential adverse effects on cardiac electrophysiology.
- Understanding these risks is crucial for safe outpatient prescribing.
Observation:
- Recent data suggest a link between azithromycin use and cardiac arrhythmias.
- The drug may induce abnormal changes in the heart's electrical activity.
- This necessitates careful consideration in clinical practice.
Findings:
- This article examines azithromycin's association with QT prolongation.
- A case-based approach is used to illustrate the risk of cardiac arrhythmias.
- The study highlights the importance of updated safety information.
Implications:
- Clinicians must be aware of azithromycin's cardiac safety profile.
- Prescribing decisions should consider potential drug interactions and patient comorbidities.
- This knowledge aids in mitigating the risk of azithromycin-induced arrhythmias.
Related Concept Videos
Endocarditis III: Medical Management
Myocarditis III: Medical Management
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Rheumatic Heart Disease III: Medical Management
Myocarditis IV: Nursing Management